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1. Introduction
Crystallization plays an important role in separation and purification of the antibiotics. And
it is also an indispensable step in preparation of pharmaceuticals with biological activities
and specific crystal form. As the last step in purification, crystallization determines the puri‐
ty, crystal habit, granularity and its distribution as well as pharmacologic effect, biologic ac‐
tivity and product stability [1], which are actually dependent on specific mechanism for its
processes and operational conditions. So it’s necessary to study thermodynamics, kinetics
and conditions of crystallization process, which helps increase the yield and reduce cost.
As a representative of macrolide antibiotics, erythromycin has been widely used since its in‐
troduction in 1952 [2]. As erythromycin derivatives, clarithomycin and azithromycin have
exhibited remarkable improvement on stability in acid solutions and metabolism dynamics
[3, 4]. A lot of researches have been done on new derivatives with features of combating
drug resistance [5, 6]. In the meanwhile, high-purity erythromycin, as the raw material, is
fundamental to produce its pharmaceutical derivatives.
Erythromycin  is  obtained  from  microbial  fermentation  in  industry.  Subsequent  separa‐
tion  and  purification  involve  multiple  unit  operations,  such  as  extraction,  absorption,
chromatography and crystallization.  Different process involves different combinations of
unit operations [7].
Among them, solvent extraction accompanied with intermediate precipitation is widely
used, in which butyl acetate is commonly adopted to extract erythromycin from the fermen‐
tation filtration. It is followed by reactive crystallization to form an intermediate prior to
conversion into erythromycin alkaline and dissolving in acetone. Lastly, erythromycin is pu‐
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rified by antisolvent crystallization [8]. That is to say, both reactive crystallization and anti‐
solvent crystallization have to be employed in this separation process.
In contrast, the technological process with membrane separation and resin absorption [9]
is drawing more attention compared with the traditional solvent extraction in the above
[10].  This process usually goes as follows: firstly, microfiltration is used to remove solid
impurities  from the  fermentation broth,  and the  filtrate  is  purified  by macroporous  ab‐
sorption resin, and then the adsorbed erythromycin is eluted with butyl acetate. Finally,
either  evaporative crystallization or  reactive crystallization can be used to obtain the fi‐
nal product [11].
Figure 1. Schematic diagram for the purification erythromycin
The flowsheet of these two technological processes is demonstrated in Figure 1. It can be
seen that crystallization is the final step to prepare erythromycin no matter which one is
adopted. Different crystallization method has been used for different pretreatment.
Crystallization  is  a  complex  process  involving  mass  transfer,  heat  transfer  and  surface
reactions,  which  includes  the  formation  of  a  supersaturated  solution,  nucleation  and
crystal growth. The operating parameters of crystallization process, such as temperature,
agitation intensity  and seed crystals,  can affect  the  generation rate  and scale  of  the  su‐
persaturation.  The  structure  of  the  crystallizers  and  stirrer  will  influence  the  fluid  me‐
chanics properties of the crystallization system. Thus it can be seen that all these factors
profoundly influence crystal nucleation and growth [12]. Over a long period of time, the
crystallization  processes  have  been  carried  out  on  according  to  experiences  rather  than
theoretical  researches  due  to  the  little  study on thermodynamics  and kinetics.  Not  sur‐
prisingly,  it’s  hardly  to  obtain  erythromycin  with  high  purity,  complete  crystal  form,
narrow  distribution  of  crystal  size,  less  crystal  bonding,  which  are  very  important  for
the stability and bioavailability of the drug.
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In  this  paper,  two crystallization  processes  of  erythromycin  in  different  systems,  which
include  the  antisolvent  crystallization  for  mixed solvents  of  acetone  and water  and the
azeotropic evaporative crystallization for butyl acetate-water system, are described in de‐
tails.  The  thermodynamics  and  kinetics  of  the  crystallization  of  erythromycin,  which
help to thoroughly understand the effect of a variety of factors on the nucleation, crystal
growth  and  crystal  habit,  are  summarized  systematically.  On  the  basis  of  these  funda‐
mental  studies,  effective  control  techniques  are  proposed  to  improve  the  quality  of  er‐
ythromycin product.
2. Purification of erythromycin by antisolvent crystallization
In the solvent extraction process for purification of erythromycin, erythromycin alkaline was
converted from erythromycin thiocyanate by adding ammonia or NaOH solution and dis‐
solving in acetone. Then erythromycin product was prepared by antisolvent crystallization,
in which water was served as antisolvent.
The traditional crystallization process, which was too simple, only involved modulating two
indicators including antisolvent quality and crystallization temperature.
Water was poured into erythromycin acetone solution at room temperature, and then the
product was obtained by filtration after standing for a period of time. Such operation made
obvious differences of supersaturation, nucleation rate and crystal growth rate and then
caused the discrepancy in product quality for different batch.
2.1. Solubility and metastable limit of erythromycin
As we know, the phase equilibrium between solid and its solution is fundamental to choose
crystallization method and also determines the maximum yield of solution crystallization
[12]. Erythromycin is soluble in acetone, but insoluble in water [13]. Thus, erythromycin can
be precipitated by adding water into erythromycin acetone solution.
2.1.1. Solubility
The solubility of erythromycin in acetone increases with the increasing temperature, where‐
as it becomes less soluble with the higher temperature in water. So, the solubility of erythro‐
mycin in acetone-water binary solvent system is influenced by the solvent composition and
temperature.
Some data on solubility of erythromycin in acetone-water solution was reported in litera‐
tures [14,15]. In this paper, the solubility above 303.15K has been measured. As can be seen
in Figure 2, the solubility of erythromycin in the medley acetone-water solution increased
with increasing acetone concentration and increasing temperature, respectively. In the same
range of acetone content, the slope of the solubility curve increased with increasing temper‐
ature, which meant the rate of increase of erythromycin solubility increased.
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Figure 2. Solubility of erythromycin in acetone-water solution at different temperatures; -□-: 293.15K; -■-: 298.25K; -
△-: 303.15K; -▲-: 308.15K; -○-: 310.15K; -●-: 312.15K; -◇-: 314.15K; -◆-: 323.15K
The impact of acetone on the solubility of erythromycin increased as the mass fraction of
acetone increasing. It was not hard to infer that the difference of the solubility at different
temperatures tended to decrease with the mass fraction of water increase.
An empirical model was proposed to relate the experimental data of the solubility of eryth‐
romycin and the parameters was obtained by fitting. The empirical equation for the solubili‐
ty of erythromycin in mixed solvents of acetone and water was expressed as below:
0.0491*
(0.0138 1.298)
1.02
0.395 0.00383
T
T
eC T x +
´= - + (1)
where C* was solubility (g Erythromycin/100g Acetone-Water Solution) and x was the mass
proportion of water to acetone (x=mw:ma). Equation (1) was practicable in the range of
293.15K≤T≤323.15K, 1.0≤x≤2.0.
Equation  (1)  could  be  used  to  calculate  erythromycin  solubility  C*Cal  under  various  ex‐
perimental conditions. The calculated solubility C*Cal  and the experimental solubility C*Exp
were  shown in  Figure  3.  It  was  indicated  that  Equation  (1)  was  appropriate  to  predict
the  solubility  of  erythromycin  within  the  range  of  temperature  and  acetone  concentra‐
tion for the equation.
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Figure 3. Comparison of simulated value and experimental data of solubility
2.1.2. Metastable zone
Metastable zone width is fundamental to choose suitable supersaturation of crystallization.
It is also used as a restrictive operating condition to avoid crystallization system going to
unstable zone [16] that results in the worse product.
Figure 4. Apparatus for antisolvent crystallization of erythromycin; 1. Thermostat Bath; 2. Circulating Pump; 3. Water
Storage Tank; 4. Peristaltic Pump; 5. Laser Generator; 6. Double-Wall Crystallizer; 7. Stirrer; 8. Thermometer; 9. Con‐
denser; 10. Laser Power Detector
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Supersolubility of erythromycin was measured by the method of laser scattering [15]. As
shown in Figure 4, the experimental device consisted of crystallizer, mixing system, feeding
system, temperature control system and detection system. Wherein, the crystallizer was a dou‐
ble-wall kettle with internal diameter 75mm and height 130mm. Stirrer with four inclined pro‐
pellers was driven by variable speed motor, the propeller diameter was 12mm, and the stirring
shaft diameter was 5mm. The peristaltic pump continuously pumped antisolvent water at a
fixed temperature into crystallizer. The detection system consisted of He-Ne laser generator
and laser power detector. He-Ne laser generator outputted 632.8nm red line, scattering and dif‐
fraction occurred when monochrome laser beam encountered with body of similar length of
wavelength, the laser intensity received by detector was drastically reduced, thus the nuclea‐
tion could be detected.
The relationship between metastable zone width ΔC of erythromycin and solvent composi‐
tion at 323.15K was shown in Figure 5. It could be seen form the figure that metastable zone
width decreased gradually with the increase of the quality of water in solution. In mw:ma
range of 1.0 to1.8, the supersolubility presented apparent downward trend. After mw:ma
reached 1.8, the change of the metastable zone width weakened, but the metastable zone
width of this region was already narrow and was not suitable for crystallization operation.
The equation was obtained by correlating the metastable zone width and solvent composi‐
tion, which was listed as follows:
2.493.09C x-D = ´ (2)
where x was the mass ratio of water to acetone, x=mw:ma.
Figure 5. Effect of solvent composition on metastable zone width of erythromycin at 323.15K
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Figure 6. The effect of stirring intensity on supersaturation of erythromycin at different temperatures; –▲–: 308.15K; –
●–: 313.15K; –■–: 323.15K
It could be seen form Figure 5, the calculated value was in good agreement with experimen‐
tal data. Similar results could be obtained at other temperatures.
As shown in Figure 6, the metastable zone width of erythromycin decreased with the in‐
crease of temperature. The metastable zone width was similar at 308.15K and 313.15K, while
it was quite different at 313.15K and 323.15K, which indicated metastable zone width was
temperature sensitive in the range of 313.15K to 323.15K. The variation of metastable zone
width with agitation power presented a consistency at different temperatures. The metasa‐
ble zone width was wider under the same agitation power at lower temperature.
2.2. Antisolvent crystallization kinetics of erythromycin
In this paper, the intermittent dynamic method [17] was used to study the kinetics of eryth‐
romycin antisolvent crystallization under different conditions. With the empirical models
deduced from the Larson-Randolph population balance equation [18,19], the model parame‐
ters were obtained from the experimental data through the matrix convertion and the meth‐
od of linear squares regression. Thus, the equations of nucleation and crystal growth of
antisolvent crystallization of erythromycin were established to help find the suitable opera‐
tion parameters.
The experimental apparatus were shown in Figure 4. Firstly, at the start of recording the
time, antisolvent water at set temperature was poured into the erythromycin-acetone solu‐
tion in the crystallizer. Once the nucleation appeared in the solution, water was stopped im‐
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porting and the time was recorded. Then the agitation rate and temperature were
maintained constant. It was sampled at different interval of time. The indexes of each sam‐
ple, such as magma density, degree of supersaturation and crystal size distribution (CSD) of
production, were measured respectively.
2.2.1. Crystal size correlation of crystal growth
The crystal nucleation and growth kinetics were solved according to the size-independent
model [16], using a set of the experimental data of magma density and CSD at 323.15K. The
calculated value was in good agreement with the experimental data, as shown in Figure 7.
In the crystal size (Li) range, erythromycin crystal population density logarithm (lnni) was
basically a straight line. At the same time, the results of matrix convertion also showed that
the use of size-dependent model to describe the crystal growth was of large error. Therefore,
erythromycin crystal growth was size-independent.
Figure 7. Typical population density distribution of erythromycin
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2.2.2. Kinetics model
On the basis of the above, the size-independent model was adopted to describe the crystal
growth rate of erythromycin. According to the study on the effects of temperature, agitation
and dosing rate of antisolvent on nucleation rate and crystal growth rate, the corresponding
equations for nucleation rate and crystal growth rate were shown as follows:
The nucleation equation
14 0.378 0 317 3 30323433.23 10 exp( ) . .V TB P MΔC T= ´ (3)
The crystal growth equation
5 0.102 3 05345391.18 10 exp( )- .VG PΔC RT= ´ (4)
where MT was magma density (kg/m3), PV was unit volume of stirring power (W/m3).
In the antisolvent crystallization of erythromycin, slurry density had less effect on the nucle‐
ation rate than supersaturation did. The influence of stirring intensity and supersaturation
on nucleation rate was greater than those on crystal growth rate. The supersaturation series
3.303 in the nucleation equation was much smaller than the primary nucleation kinetics ser‐
ies [12]. So the mechanism of nucleation of antisolvent crystallization of erythromycin was
secondary nucleation.
2.2.3. Online study of crystallization process
In order to further reveal the intrinsic principles of the antisolvent crystallization process
of  erythromycin,  the  Focused  Beam  Reflectance  Measurement  (FBRM)  technique  was
adopted to monitor in situ the variation of  crystal  quantity and crystal  size distribution
in this paper.
The total number and the chord length distribution (CLD) of crystal particles were meas‐
ured by using the equipment and method shown in literature [20]. A mathematical pro‐
cedure  based  on  Monte  Carlo  simulation  was  established  to  transform  the  CLD  into
CSD.
The change of the number of crystals and CSD of erythromycin antisolvent crystallization
were studied under different temperature and feeding rate of antisolvent. The results indi‐
cated that the faster water was fed, the earlier new crystals came into being, the faster the
crystal grew at the initial stage. The total number of crystals at the stable stage tended to
decrease as temperature increased [20].
Purification of Erythromycin by Antisolvent Crystallization or Azeotropic Evaporative Crystallization
http://dx.doi.org/10.5772/52934
51
Figure 8. CSD after peak value of overall crystal number count at 308.15K; –■–: 0min; –●–: 30min; –▲–: 90min; –◆–:
180min
Figure 9. CSD after peak value of overall crystal number count at 314.15K; –■–: 0min; –●–: 30min; –▲–: 90min; –◆–:
180min
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The proportion of particles of different size was the grain size frequency distribution. Figure
8 and Figure 9 showed the size frequency distribution curve after nucleation at 308.15K and
314.15K respectively. As could be seen from those, the curves were similar at different tem‐
peratures, which were sharp and steep. Particle size which was less than 20μm accounted
for the vast majority and the peak of the curves was close to 20%.
It could be found from Figure 8 and Figure 9 that the number of both small size crystal and
large size crystal hardly change with time. It meant that particles with small size were con‐
stantly dissolving, while saturated solute of erythromycin was precipitated to form new
crystal, or the existing crystal grew larger in volume. The dissolution and precipitation of
erythromycin reached equilibrium.
In order to properly characterize the crystal growth, volume mean diameter DV (also known
as D43) which was the equivalent diameter of the particles with same volume (or mass), was
used to investigate the changes of crystal size with time at different temperatures. As shown
from Figure 10, erythromycin DV monotonically decreased with the increasing temperature
at the same crystallization time.
Figure 10. The effect of temperature on Dv of erythromycin crystal; -■-: 0min; -□-: 30min; -●-: 60min; -○-: 90min; -▲-:
120min; -△-: 150min; -◆-: 180min
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2.3. The antisolvent crystallization technique of erythromycin
The thermodynamics and kinetics of the antisolvent crystallization of erythromycin were
summarized systematically to understand thoroughly the effect of a variety of factors on the
nucleation, crystal growth and crystal habit. On the basis of these fundamental studies, ap‐
propriate technological parameters were explored to develop the efficient industrialized
crystallization process of erythromycin.
2.3.1. Technological parameters
Crystal quality, such as crystal purity, crystal habit, crystal size, and CSD, was related close‐
ly to the crystallization conditions. Accordingly, the effect of the dosing rate of antisolvent,
crystallization time, stirring intensity and crystallization temperature on CSD of erythromy‐
cin was studied in details in this paper.
Dosing rate of antisolvent For antisolvent crystallization of erythromycin, the dosing rate of
antisolvent determined the generation rate of supersaturation, and also affected the rate of
nucleation and crystal growth.
The definition of dosing rate of antisolvent was the importing water volume of per unit time
and per unit volume of erythromycin-acetone solution.
wd
Vv V= (5)
where vd was dosing rate of antisolvent (min-1), Vw was the volume rate of importing water
(mL/min), V was the erythromycin-acetone volume (mL).
Figure 11 showed the relationship between the dosing rate of antisolvent vd and erythromy‐
cin CSD, where dp was the crystal diameter and Rv was the cumulative volume fraction. It
could be seen from the figure that the proportion of crystals with large size increased with
the increasing dosing rate of water, but the CSD tended to disperse. While the CSD of crys‐
tals obtained in lower water dosing rate was more concentrated.
Therefore, in process of the crystallization, an appropriate increase in generation rate of su‐
persaturation could speed up the crystallization rate and improve the capability of the crys‐
tallizer. However, the rapid generation of crystals will increase the chance of crystal
breakage and secondary nucleation and make the CSD disperse.
Crystallization time The cumulative volume distribution at different crystallization time
was shown in Figure 12, where dp was the crystal diameter and Rv was the cumulative vol‐
ume fraction. As could be seen from the figure, the increase of the crystallization time was
conducive to crystal growth, while the CSD did not tend to concentrate. The crystal growth
needed some time, however, long time crystallization couldn’t promise CSD being more
consistent.
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Figure 11. CSD based on cumulative volume of erythromycin at different water-pumping velocities; -▲-: 0.0138min-1; -
●-: 0.188 min-1; -■-: 0.024 min-1; -◆-: 0.0389 min-1
Figure 12. CSD of erythromycin based on cumulative volume at different crystallization time; -▲-: 40min; -●-: 50min; -
■-: 70min: -◆-: 100min
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Agitation power The CSD was the result of the interaction of primary nucleation, secondary
nucleation, and crystal growth. Meanwhile, agitation power had a significant impact on all
the above. Figure 13 showed the particle volume distribution of erythromycin at different
stirring intensity, where xv was the particle volume distribution.
It could be seen from Figure 13 that the erythromycin product had the widest CSD and the
highest proportion of small size crystals when the stirring power was 13.99 W/m3, and the
distribution curve had smearing phenomenon in the range of large particle size. While the
crystal had the narrowest CSD and the lowest proportion of small size crystals when the
stirring power was 1.749 W/m3, and the distribution curve had no smearing. The energy im‐
ported by stirring was conducive to nucleation and crystal growth. In the meanwhile, crys‐
tal breakage could easily occur with too strong stirring, while the obvious differences of
supersaturation would occur with too weak stirring and then caused variation of rate of nu‐
cleation and crystal growth.
Figure 13. CSD based on volume of erythromycin at different agitation power; -■-: 0.02179W/m3; -●-: 1.749 W/m3; -
▲-: 13.99 W/m3
Crystallization temperatureFigure 14 showed the variation of volume mean diameter (DV)
of erythromycin at different crystallization temperature, DV decreased with the increasing of
temperature. The previous thermodynamic study showed that the metastable zone width of
erythromycin reduced with the increase of temperature. The intensified thermal motion of
molecule caused by the increasing temperature accelerated the frequency of contact and col‐
lision of crystals, and then promoted the formation of tiny crystals, and decreased the super‐
saturation required for nucleation. On the other hand, the driving force of crystallization
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decreased with the narrowing metastable zone width, so did the rate of crystal growth.
Therefore the volume mean diameter of the crystals decreased as the temperature increased.
Figure 14. Volume mean diameter of erythromycin at different temperatures
2.3.2. The novel technique of antisolvent crystallization of erythromycin
For the traditional antisolvent crystallization, water was poured into erythromycin acetone
solution at room temperature. Then after standing for a period of time, the erythromycin al‐
kaline product was obtained by filtration.
It was not difficult to find the shortages of this crystallization method. Firstly, the dosing
rate of antisolvent was too fast. When the antisolvent water was fed rapidly, the supersatu‐
ration formed suddenly and leaded to the outbreak of the nucleation. Nucleation was active
and occupied the dominant position of the crystallization process. Meanwhile, the impuri‐
ties easily accompanied with crystals by precipitation in the fast crystallization process. Sec‐
ondly, stirrer and stirring intensity were inappropriate. Poor mixing effect made uneven
distribution of supersaturation, so it was hard to obtain erythromycin with complete crystal
form and narrow distribution of crystal size [12,21]. Thirdly, crystallization temperature was
uncontrolled. Then the differences of solubility between erythromycin and impurities in ace‐
tone-water solution could not be fully explored to improve the separation efficiency.
The operation of the crystallization mentioned above lacked of crystallization process con‐
trol and could not play a good role in purification of erythromycin by crystallization. Then
the erythromycin product would be highly influenced by fermentation broth and pre-purifi‐
Purification of Erythromycin by Antisolvent Crystallization or Azeotropic Evaporative Crystallization
http://dx.doi.org/10.5772/52934
57
cation. That was to say, the quality of erythromycin was restricted by erythromycin thiocya‐
nate. So it was hard to obtain the erythromycin product with stable and high quality and
yield.
There were some other studies [8,22] on the improvement of erythromycin crystallization
method by adding seed crystals.
On the basis of thorough research on the antisolvent crystallization process of erythromycin,
a novel technique for antisolvent crystallization of erythromycin by dynamic control of tem‐
perature and stirring power was proposed in this paper, which was listed as follows.
1. Dosing the antisolvent. The polarity of mixed solvents was changed gradually when the
antisolvent was imported into erythromycin acetone solution slowly. In the meantime,
the solubility of erythromycin decreased gradually until crystal nucleus formed. The su‐
persaturation could be controlled within the thermodynamic metastable zone by dosing
antisolvent continuously, the crystal growth was moderated and in order, and the CSD
of erythromycin tended to be narrow.
2. Appropriate stirring intensity. The suitable stirring power could be conducive to main‐
taining uniform supersaturation and crystallization rate. Meanwhile, stirring could pro‐
mote dynamic balance of crystallization and dissolution, and reduce the crystal
bonding, and then improve the purity of the crystal.
3. Increasing nucleation temperature. Substance usually had higher solubility at a higher
temperature, so did the impurities. Increasing nucleation temperature could reduce the
chance of impurities precipitation and improve the purity of erythromycin.
4. Cooling crystallization and aging with lower stirring intensity. After nucleation at high
temperature, the stirring power should be reduced to avoid excessive shear force on the
crystal collision and maintain a uniform concentration distribution in the slurry at the
same time. Then, the supersaturation produced by cooling maintained crystal growth at
a steady rate after dosing all antisolvent. Lastly, aging with lower stirring power at low‐
er terminal temperature could improve the quality and yield of product.
On the basis of the above, the key operation parameters which affect the quality of crystal,
such as temperature, dosing rate of antisolvent and stirring intensity, were determined by
measuring the crystal shape, titer and yield [23]. Then the novel technique of erythromycin
antisolvent crystallization was established in this paper, which was characteristic of dynam‐
ic control of temperature and stirring intensity [24].
Figure 15 and Figure 16 showed the crystal shape and CSD of industrial erythromycin prod‐
ucts obtained by the traditional method (a) and novel technique (b), respectively. For the
crystal shape, product (b) had a more regular and bigger size than product (a) did. For the
CSD, product (b) was narrower. For titer, product (b) was 935.6 U/mg, while product (a) was
920 U/mg. Those meant that the quality of erythromycin had been improved by the novel
technique of antisolvent crystallization [23].
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Figure 15. Crystal shape of erythromycin from different antisolvent crystallization processes [23]; (a) traditional proc‐
ess; (b) novel process
Figure 16. CSD of erythromycin from two antisolvent crystallization processes [23]; (a) traditional process; (b) novel
process
In the commercial  use of  the antisolvent crystallization process,  erythromycin with high
specific  activity  was  obtained  at  high  yield.  Over  90%  of  the  products  met  the  de‐
mands  per  year,  which  was  much higher  than the  53% with  the  traditional  crystalliza‐
tion process.
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3. Purification erythromycin by azeotropic evaporative crystallizaion
The development of the crystallization technique of erythromycin is limited to some extent
by the extraction and purification prior to the crystallization. Taking the production of er‐
ythromycin as an example, the widely used process is frame filtration of fermentation broth
- solvent extraction - salting-out crystallization – alkalization - antisolvent crystallization.
Due to the limited interception capability for fine particles and macromolecules impurities
such as proteins by frame filtration, and the low selectivity of the object over pigment and
the small un-ionized organic molecules by solvent extraction, the impurity content is high in
the organic phase. Therefore, the object should be further purified by coupling two crystalli‐
zation methods in the subsequent refining process.
In recent years, a different technological process by membrane separation and resin absorp‐
tion is gradually introduced into industrial application [25,11]. The process consists of sever‐
al steps including membrane separation, resin absorption, elution and crystallization.
Firstly, microfiltration is used to remove mycelium, a variety of fine suspension particles
and some protein from fermentation broth, then pigment and small un-ionized organics are
removed by resin absorption and the elution with butyl acetate. An improvement of the pu‐
rity of erythromycin butyl acetate solution is obtained by using this pretreatment. And it
makes crystallization preparation of erythromycin alkaline from butyl acetate elution be‐
come possible.
For the preparation of erythromycin alkaline from erythromycin butyl acetate solution, the
product yield is low due to the high solubility of erythromycin. So the urgent task is to in‐
crease the yield. To remove butyl acetate is feasible, while high temperature for solvent
evaporation may cause the destruction of erythromycin. Although erythromycin has better
thermal stability than some other sorts of antibiotics, there is no precedent on the separation
and purification of erythromycin with temperature being above 323.15K in industrial appli‐
cation till now. Thus, azeotropic evaporative crystallization of erythromycin is proposed in
this paper. The method takes erythromycin, butyl acetate and water as crystallization sys‐
tem. Then butyl acetate-water azeotrope is removed by vacuum azeotropic evaporation to
make erythromycin precipitate and disperse into water. Excessive water is added to the er‐
ythromycin butyl acetate solution for azeotropic evaporation, which can also play a role of
washing crystals. The solubility of butyl acetate in water is quite small, so the azeotrope is
easy to split into two phases at room temperature. The schematic diagram of azeotropic
evaporative crystallization of erythromycin is demonstrated in Figure 17.
The solubility of erythromycin in butyl acetate-water saturated solution (solution A) and in
water-butyl acetate saturated solution (solution B) was detected, respectively. The result in‐
dicated that the solubility of erythromycin in solution A was quite low and had little change
with temperature. So for the azeotropic evaporative crystallization of erythromycin, the pro‐
portion of water was based on its effect on operation, such as the viscosity of the solution
and crystal dispersion, as well as the utilization of equipment and the efficiency of produc‐
tion, rather than on the yield of crystallization.
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Figure 17. Principle illustration for azeotropic evaporative crystallization process of erythromycin
3.1. Technological parameters
Once the azeotropic evaporative crystallization of erythromycin was established, the optimi‐
zation of parameters was directed by the quality and yield of crystal. The process parame‐
ters related to the crystal shape, crystal size and CSD were shown as follow: firstly, the
supersaturation, which was related to the quantity of butyl acetate removed by azeotropic
evaporation; secondly, the generation rate of supersaturation, which was dependent on the
azeotropic evaporation rate and the cooling rate; thirdly, the crystallization temperature,
which was bound up with vacuum of system and the cooling rate; fourthly, the stirring in‐
tensity, and etc,. The yield of erythromycin was determined by the evaporation quantity of
butyl acetate and the terminal crystallization temperature.
System vacuum and operation temperature The butyl acetate-water azeotrope was re‐
moved from the crystallization system by vacuum evaporation, and the azeotropic tempera‐
ture varied with the pressure. Then the high temperature leading to the damage of
erythromycin could be avoided by adjusting the pressure.
According to the phase equilibrium data reported in the literatures [26,27], the azeotropic
temperature and composition under different vacuum was calculated by using Pro II simu‐
lation software and NRTL thermodynamic model. When the system vacuum was controlled
above 0.084MPa, the crystallization temperature was below 323.15K.
Supersaturation The supersaturation of erythromycin increased with the increasing volume
of butyl acetate evaporated. The supersaturation varied with temperature and evaporation
volume of butyl acetate, which affected CSD of the product.
Figure 18 showed the relationship between the cumulative volume distribution and supersatu‐
ration at 316.15K, where dp was the crystal diameter and Rv was the cumulative volume frac‐
tion. As can be seen from the figure, the crystal size of erythromycin increased with the increase
of supersaturation. However, it was necessary to choose the supersaturation range carefully
due to the variation of solution viscosity and the difficulties of the crystal dispersion.
Cooling rate The cooling crystallization started after evaporating some amount of butyl ace‐
tate. The supersaturation caused by cooling made the crystallization process proceed contin‐
uously. It could improve the quality yield of the product by reducing the terminal
crystallization temperature.
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Figure 18. CSD based on cumulative volume of erythromycin at different supersaturation -■-: 39.91 g/100g; -▲-:
40.76 g/100g; -●-: 41.26 g/100g; -◆-: 41.60 g/100g
Figure 19 showed the relationship between the cumulative volume distribution of erythro‐
mycin and cooling rate, where dp was the crystal diameter and Rv was the cumulative vol‐
ume fraction of the crystal. It could be seen form the figure that speeding up the cooling rate
was not conducive to the growth of crystal and made the crystal size decrease.
Figure 19. CSD based on cumulative volume of erythromycin at different cooling rate -■-: 273.17K/min; -●-:
273.20K/min; -▲-: 273.28K/min
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3.2. The technique of erythromycin azeotropic evaporative crystallization
On the basis of the studies above, the crystallization technique combining the azeotropic
evaporation with cooling crystallization was established to prepare the erythromycin from
erythromycin butyl acetate solution directly. This process included mainly the following
steps: firstly, introduction of entrainer. Adding entrainer (water) to erythromycin butyl ace‐
tate solution could form azeotropic crystallization system and decrease the evaporation tem‐
perature; secondly, vacuum evaporation. Adjusting the vacuum could promise the
azeotropic evaporation temperature of butyl acetate and water was low enough to avoid the
destruction of erythromycin; thirdly, appropriate evaporation quantity of butyl acetate. The
supersaturation could be maintained within the thermodynamic metastable zone by adjust‐
ing the evaporation quantity of butyl acetate; fourthly, modulating cooling rate. The rate of
crystallization could be regulated by adjusting cooling rate, so the supersaturation produced
by cooling also could be maintained within the thermodynamic metastable zone to promise
crystal growth; finally, the agitation power should be adjusted with the variation of crystal‐
lization stages.
There was an application for erythromycin purification by azeotropic evaporative crystalli‐
zation. The technological conditions were listed as follows, the raw material of erythromycin
was provided by a pharmaceutical company, the volume of water in the crystallization sys‐
tem was three times the volume of butyl acetate, the supersaturation was about 45g erythro‐
mycin/100g butyl acetate, cooling rate was 273.22K/min, the terminal crystallization
temperature was 303.15K. With the conditions above and the technology in this paper, the
purity of erythromycin A in the product was 95.87% and the yield in mass was 75.7%, which
was higher than the yield 64.6% of erythromycin product by traditional antisolvent crystalli‐
zation process using the same batch of raw materials.
4. Conclusion
In this paper, the thermodynamics, crystallization kinetics and operating conditions were
studied systematically for the antisolvent crystallization of erythromycin. A brand-new tech‐
nique with dynamic control of temperature and agitation intensity was henceforth present‐
ed. This process included nucleation at high temperature (313.15K~323.15K), regulation of
temperature and agitation power according to the different stage of nucleation, crystal
growth and crystal aging. It made the operation parameters of crystallization process more
reasonable, and the erythromycin with high specific activity had high yield. The commercial
use of the antisolvent crystallization technique had been successful.
Meanwhile, a novel purification method of erythromycin by azeotropic evaporative crystal‐
lization was also put forward. With this method, erythromycin could be produced from er‐
ythromycin butyl acetate solution directly. By the introduction of water, the evaporation
temperature of azeotrope of butyl acetate and water was decreased and the supersaturation
was induced. Then, crystallization nucleation and crystal growth were controlled by the reg‐
ulation of cooling rate. With the azeotropic evaporative crystallization, qualified erythromy‐
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cin product could be obtained without recrystallization, which leaded to less solvent
consumption, simplified purification process and crystal product with narrow size distribu‐
tion and perfect crystal shape.
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